Drawing based on the label description. No photo yet.
“RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with 'a45' on one side”
a45 pill
Pill with imprint a45 is yellow, capsule, 14 mm and has been identified as Upadacitinib 45 mg. It is used for rheumatoid arthritis. It is supplied by Abbvie Inc.
Upadacitinib 45 mg
- Imprint
- a45
- Strength
- 45 mg
- Used for
- Rheumatoid arthritis
- Color
- Yellow
- Shape
- Capsule / oblong
- Size
- 14 mm
- Score
- No score line
- Form
- Tablet, extended release
- Manufacturer
- Abbvie Inc
- Drug class
- Cancer medicine (kinase inhibitor)
- NDC
- 0074-1043, 0074-1043-28, 0074-1043-14
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Upadacitinib used for?
Upadacitinib is used for rheumatoid arthritis.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
Rheumatoid Arthritis
RINVOQ® is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
Psoriatic Arthritis
RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Atopic Dermatitis
RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Ulcerative Colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for UC, or with potent immunosuppressants such as azathioprine and cyclosporine.
Crohn’s Disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers. If TNF blockers are clinically inadvisable, patients should have received at least one approved systemic therapy prior to use of RINVOQ.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for CD, or with potent immunosuppressants such as azathioprine and cyclosporine.
. 6 Ankylosing Spondylitis
RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
. 7 Non-radiographic Axial Spondyloarthritis
RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Polyarticular Juvenile Idiopathic Arthritis
RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an inadequate response or intolerance to one or more TNF blockers.
- Limitations of Use: RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
Giant Cell Arteritis
RINVOQ is indicated for the treatment of adults with giant cell arteritis.
- Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
From the FDA-approved label on DailyMed (published Jul 15, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows a45 and the other side has no imprint.
- It is yellow, capsule, 14 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold under the brand name Rinvoq.
Ingredients
Active: Upadacitinib
Inactive: Silicon Dioxide, Hypromellose, Unspecified, Ferric Oxide Yellow, Ferric Oxide Red, Magnesium Stearate, Mannitol, Microcrystalline Cellulose, Polyvinyl Alcohol, Unspecified, Polyethylene Glycol, Unspecified, Talc, Tartaric Acid, Titanium Dioxide
Other pills with imprint A45
Same imprint, different listing. Check the color, size and maker against your pill.
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
Y201 20mg
Duloxetine Hydrochloride 20 mg
Yellow, capsule, 14 mm
Used for nerve pain from diabetes and anxiety
-
SD TC 1 mg
Tacrolimus 1 mg
Orange & yellow, capsule, 14 mm
Used for eczema
-
G 583
Aprepitant 40 mg
White & yellow, capsule, 14 mm
Used for nausea and vomiting
-
G 685
Tacrolimus 0.5 mg
Yellow, capsule, 14 mm
Used for eczema
-
F 42
Atomoxetine 18 mg
White & yellow, capsule, 14 mm
Used for ADHD
-
AN 783
Memantine Hydrochloride 14 mg
Green & yellow, capsule, 14 mm
Used for Alzheimer's disease
